Weight-loss drug stocks have been in focus during the last year due to a rapidly expanding addressable market. According to an industry report, the global weight-loss drugs market is forecast to rise from $3.83 billion in 2023 to $44.12 billion in 2029, indicating annual growth rates of roughly 50% year over year.
In recent years, healthcare giants such as Novo Nordisk (NVO) and Eli Lilly (LLY) have unveiled weight-loss drugs to address these markets. Moreover, these companies are investing heavily in research and development to introduce safer, more effective weight-loss medications, and to gain traction in this robust market.
